Cytokine-secreting, major histocompatibility complex-unrestricted activated killer (AK) cells are toxic t o a wide range of virus-infected or malignant target cells and may be generated endogenously, eg, after bone marrow transplantation, or by infusion of cytokines such as recombinant interleukin-2 (rlL-2). Although AK cells secrete cytokines such as y-interferon and tumor necrosis factor, which are themselves able t o recruit fresh cytokine-secreting AK cells, activation in both settings is short-lived, implying the existence of homeostatic regulatory mechanisms. We now demonstrate one mechanism by which rapid homeostasis is achieved. We show that IL-4 is produced in patients with both endogenously and exogenously generated AK cells. The cytokine was detected in serum after marrow transplantation, and IL-4 transcripts CTIVATED KILLER (AK) lymphocytes with major
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A histocompatibility complex (MHC)-unrestricted activity may be an important initial defense mechanism against viruses and malignant cells. These phenotypically heterogenous cells may be derived from CD3TD16-T cells or from CD3-CD16' natural killer (NK) cells and are produced endogenously, eg, after bone marrow transplantation (BMT) and some types of chemotherapy, and may contribute to the antineoplastic activity of these procedure^.'.^ AK lymphocytes can also be produced by infusion of pharmacologic doses of recombinant interleukin-2 (rIL-2).5-8 Both endogenously and exogenously generated AK cells are directly toxic to a range of target cells, and they secrete at least two cytokines, tumor necrosis factor (TNF) and y-interferon (7-IFN), which contribute to their cytotoxic effector funct i~n .~. "
TNF and y-IFN may also be able to recruit fresh, cytokine-secreting AK cell^.^^,'^ Despite this potential for establishing an uncontrolled positive feedback loop, both endogenous and exogenous AK functions are of limited degree and of brief duration, an observation strongly suggesting the presence of potent homeostatic regulatory mechanisms. The short half-lives of these cytokines in vivo and the internalization of their cellular receptors after ligand binding may both contribute to homeostasis.6-8 We have examined whether the process of generating AK cells in vivo itself leads to the production of cytokines, which limit the recruitment of fresh AK cells and abbreviate their activation. One candidate for this homeostatic activity is IL-4, a T-lymphocyte-derived cytokine with pleiotropic effects on the hematopoietic and immune ~ystems.'~"~ IL-4 promotes the growth and/or differentiation of T cells, B cells, mast cells, monocytes, and hematopoietic progenitor cells.'"*' It also has contrasting effects on cytotoxic effector lymphocytes. It stimulates the generation of MHC-restricted, antigen-specific cytotoxic T cells, but it has been shown in vitro to inhibit induction of MHCunrestricted, antigen-nonspecific AK cells when lymphocytes are exposed to stimuli such as IL-2 in To assess whether IL-4 has a physiologic role in modulating AK function, we determined whether this cytokine is produced in vivo in patients in whom AK generation has appeared in circulating lymphocytes during rlL-2 infusion. Although IL-4 inhibited the induction phase of AK cell function, it had no significant inhibitory effect on the ability of AK cells from these individuals t o respond t o restimulation. Nonetheless, neutralization of the IL-4 induced during cell activation doubled the half-life of AK function, once activating stimuli were removed, from 18 t o 44 hours and produced a 2-log increase in AK cell secretion of tumor necrosis factor and y-interferon. These data suggest that IL-4 induced in vivo during lymphocyte activation abbreviates AK cell responses once the triggering stimuli have been removed. Neutralization of endogenous IL-4 in vivo by appropriate monoclonal antibodies might prolong the duration of AK function.
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occurred physiologically or as a consequence of rIL-2 infusion. We also have investigated how IL-4 modifies AK cell function and the cytokines they secrete, by adding IL-4 and by neutralizing endogenous IL-4 in both groups of patients.
MATERIALS AND METHODS

Patients.
Thirty patients and seven normal donors were studied. Endogenous AK function was studied in 22 patients after BMT for hematologic malignancies. Fourteen patients had received cryopreserved autologous bone marrow during BMT for acute myeloid leukemia (AML; n = 6), early pre-B acute lymphoblastic leukemia (ALL; n = 4), or T-cell ALL, B-cell ALL, multiple myeloma, or Hodgkin's lymphoma (n = 1 each). Eight patients had undergone allogeneic BMT for AML (n = 3), T-cell ALL (n = 2), or early pre-B ALL, pre-B ALL, or chronic myeloid leukemia in chronic phase (n = 1 each). Marrow was obtained from HLAidentical donors depleted of T cells in vitro by incubation with Campath IgM antibody plus autologous serum (three cases) or with anti-CD5 Ricin A chain immune conjugate. No routine posttransplant immunosuppression was used. Two patients developed grade I graft-versus-host disease and were treated with a short course of methylprednisolone during which they were not investigated for the present study. Patients received transplants after conditioning with cyclophosphamide (60 mgkg x 2) plus Mesna i f they wen in first remission, or with cyclophosphamide (MI mg/kg x 2) plus Mesna and cytarabine (1 to 3 glm' x 6) if they were in second or subsequent remission, and with a single dose of total-body irradiation at a maximum prescribed dose of 750 Gy to the lungs.
Exogenously induced AK function was studied in eight patients who received rIL-2 therapy. Two patients were in remission of multiple myeloma after autologous BMT and six patients had solid tumors (three renal carcinomas, two malignant melanomas, one colorrctal carcinoma). The I G 2 administration schedule and the clinical effects have been described in detail elsewhere."
With approval of the Ethical Practices Committee of the Royal Free Hospital (London, England), 60 to 100 mLof blood was drawn from patients 3 to 8 weeks after transplantation, or before. during, and after I L 2 infusion.
After centrifugation on Lymphoprep (Nycomed. Oslo, Noway) and washing in RPMl 1640 (Flow Lab, McLean. VA), peripheral blood mononuclear cells (PBMC) were resuspended in RPMl supplemented with 2 mmoVL glutamine, penicillin 100 IU/mL, streptomycin 100 pg/mL (GIBCO, Gaithersberg, MD), and 10% volhrol heat-inactivated fetal calf serum (FCS; Sera Laboratories.
Crawley, England).
Cyokines. r l L 2 cloned in Escherichicr coli, with a specific activity between 1.7 and 3.2 x 10" U/mg protein, was provided by mtWA airuction andanalysis Cytoplasmic RNA was extracted from PBMC using the detergent lysis method.n Briefly, cells were washed in phosphate-buffered saline (PBS) and resuspended in hypotonic buffer (10 nmol/L Tris HCL, pH 7.8; 150 mmol/L NaCI) containing 10 mmol/L Vanadyl ribonuclease complex (BRL, Uxbridge, England) and 1% NP 40 (Shell Chemicals, London, England). The nuclei were pelleted by centrifugation, and the cytoplasmic extract was mixed with an equal volume of extraction buffer (40 mmoVL Tris HCL, pH 7.8; 40 mmoVL EDTA, pH 8.0; 7 0 mmoVL NaCI; 2% sodium dodecyl sulphate [SDS]). The supematant was extracted twice with phenokhloroform and once with chloroform/isoamyl alcohol. RNA was precipitated after adding 2.5 vol of 100% ethanol, and stored at -7WC.
Northem blots. After quantification, RNA specimens (between 20 and 50 pg of RNA) were size fractionated on 1% denaturing gels containing 6% formaldehyde. After ethidium bromide staining showed the RNA was nondegaded and equally loaded, the RNA was transferred avemight to nitrocellulose.
Filters were baked for 2 hours at 80°C and prehybridized in 50% formamide. 5X saturated sodium citrate (SSC), 5X Denhardt's solution, and 0.5% SDS 50 p@mL denatured salmon sperm DNA at 42°C for 4 to 8 hours. After hybridization with an IL4 probe (a 900-bp Eco-RI-SPI fragment from Dr E. Kawashima, Glaxo IMB) labeled by random oligoprimin$ for 16 hours at 42°C. filters were washed twice in 2X SSUO.l% SDS at mom temperature and twice in 0.2X SSC/O.l% SDS at 65°C and exposed to Fuji Rx film for 1 to 10 days at -70°C. A dot-blot The plates were washed six times with 5% milWBS, and a second l's-labeled MoAb was added. The labeled antibody was left for 2 hours at room temperature before washing. Bound radioactivity was measured in a gamma counter. A National Institute for Biological Standards and Control (Hertfordshire, England) IL-4 standard (89/508) was included in all assays. The detection limit of the assay was 30 pg/mL. For in vitro 1L-4 production a commercially available R + D Quantikine (Minneapolis, MN) enzymelinked immunosorbcnt assay (ELISA) was used. Detection limit was =20 pglmL.
TNF ELISA. Immunoassay was perfonned using either a double-antibody sandwich technique' calibrated with an interim TNF standard (86/659) with a detection limit of 1 
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Diagnostics Ltd. Slough, England). The detection limit of the assay was 1 U/mL 7-IFN.
PBMC were resuspended in supplemented RPMI 1640 medium with 10% voVvol FCS at a concentration of 2.5 x l(r/mL and cultured in medium alone, rIL2 at a concentration of 500 U/mL, 1 1 4 at IO ng/mL, or both cytokines in combination. In some experiments, anti414 MoAb or polyclonal antibody (5 to 10 pg/mL) was used. The cells were washed and used as effector cells, either fresh or after 3 days of culture at 3PC in 5% Tatger cell lines. The target cell for the lymphokine-activated killer (LAK) cell assay was an NK-resistant Epstein-Barr virustransformed 9-lymphoblastoid cell line (EBV-LCL) established from the peripheral blood of a normal donor as described previCyfotmciiry assoy. A 4-hour "Cr release assay was used to determine cytotoxic effector function. Target cells were labeled with "Cr (Na,Cr"O,) for 90 minutes at 37°C and 5% CO,, washed, and resuspended in supplemented RPMI/lO% FCS. One hundred microliters of target cells at a concentration of 5 x IWmL was mixed with 100 pL of effector cells at three concentrations (highest effector-to-target cell ratio = 50:l). All estimations were performed in triplicate. Maximum and spontaneous release were measured by using supernatants from targets incubated with 1% Triton-X (Sigma, St Louis, MO) or RPMI 1640/10% FCS alone, respectively. Plates were incubated at 37°C in 5% CO, for 4 hours. Finally, the plates were spun and 100 pL of supernatants was collected for isotope counting. Percent specific cytotoxicity was calculated as: 
RESULTS
It-4 is induced during endogenous and emgenous (rlL-2-mediated) lymphocyte activation. IL4 is not generally detected in the serum of healthy donors (Fig l) . However, after BMT, when there is a spontaneous activation of cytotoxic lymphocytes,u IL4 was found in the serum from seven of nine patients. Serum I L 4 levels did not increase during 5day infusions of rIL2 in patients with malignant disease. Nonethcless, there was evidence for I L 4 induction, as transcripts for the cytokine were found in RNA extracted from lymphocytes within 48 hours of beginning rIL2 infusion (Fig 2) , and these cells produced 87,137, and 214 U of IL-4 after 48 hours of further in vitro culture in 50 U/mL IL-2. When normal (nonactivated) PBMC are exposed to IL2, I L 4 inhibits the generation of LAK cells.Zzu We investigated whether IL4 had a similarly suppressive effect when it was added to the endogenously activated lymphocytes that circulate after BMT.2-'
Effect of IL-4 on AK cell function after BMT.
To validate the system, we isolated PBMC from seven normal donors and cultured them for 3 days with medium alone, with rIL-4 at 10 ng/mL, with rIL-2 at 500 U/mL, and with both cytokines. The cytotoxic activity of these cffector cells was measured against an NK-resistant but LAKsensitive (EBV-LCL) target cell line. At the beginning of culture, normal donor lymphocytes did not kill LAK targets (Fig 3A) . In the presence of IL-2, LAK activity was induced and a mean of 21% of the EBV-LCL targets were killed (Fig 3A) . Addition of rIL4 alone did not induce LAK activity in these normal donor cells (Fig 3) . but the presence of rIL-4 in the IL-2-stimulated cultures substantially inhibited LAK cell generation with a mean killing of only 11.2% 2 1.2% ( E T ratio = 501; P = .002).
We next studied the effects of IL-4 on the preactivated lymphocytes circulating in BMT recipients. These cells have spontaneous AK activity (Fig 3B) . and CD25' (IL-2 receptor) lymphocytes form 13% -C 4% of the total in the PBMC population compared with less than 1% of total PBMC in normal controls. With the addition of rIL-2 there was an increase in AK activity, whereas IL-4 alone had no effect (Fig 3B) . In these patients, IL4 only slightly inhibited thc augmcnted AK function generated by exposure to IL-2, reducing the mean cytotoxic activity in 17 patients from 33.9% to 27.4% (see Fig 3) . a difference that did not attain statistical significance. Thus, IL-4 has less effect on the augmentation of AK function than it does on its induction.
Effect of IL-4 on AK cell function of !ymphqtes from patients wceiving rlL-2. To further define the limitations of IL-4 inhibition of IL2-dependent AK function, we studied the effects of culturing PBMC from patients receiving IL-2 infusions. The peripheral blood lymphocytes from (Fig 5) . However, in the presence of IL-4 antibody this half-life could be extended to a mean of 44 k 7 hours To investigate whether the effects of IL-4 on the activation half-life of AK cells could also be associated with a reduction in the release of cytokines capable of recruiting fresh AK cells, we initially cultured lymphocytes from normal donors with IL-2 and anti-IL-4. Table 1 shows that anti-IL-4 but not a control IgG, MoAb enhanced secretion of y-IFN and TNF. We then cultured IL-2-stimulated lymphocytes from patients, with or without neutralizing anti-IL-4 antibody, and measured the production of y-IFN and TNF. Table 2 shows that in the presence of antibody, secretion of both TNF and y-IFN could be increased more than 10-fold over a 48-hour period' (P < .001).
IL-4 reduces secondaiy cytokine secretion. 
DISCUSSION
we have shown that I L -~ acts as a homeostatic agent for AK1ymphomes7 whether these cel1s are generated endogenously, eg, after BMT, or by the infusion of rIL-2-Thus, body on prolongation of cytotoxic activity (P < .MI).
these patients have significant AK function (Fig 3C) , and approximately 15% are CD25'.' Cytotoxicity can be further augmented by addition of fresh rIL-2 in vitro (Fig 3C) . IL-4 again has no direct stimulatory effect and, in this setting, it is entirely unable to modify the increase in AK function induced by fresh rIL-2 ( Fig 3C) .
These data suggest that even though IL-4 is induced during cell activation, the cytokine has little role in inhibiting further responsiveness to fresh stimulatory signals. We investigated whether endogenous IL-4 had an alternative homeostatic role in terminating the AK response once the initiating stimulus is removed. We cultured, in medium alone, PBMC from patients who had undergone BMT and measured AK activity at the beginning of culture and 3 days later. At the termination of culture in medium alone, AK activity had decreased to background. However, in the presence of anti-IL-4 antibody AK activity was maintained throughout the 3-day culture period in all four patients studied (Fig 4) . More detailed analysis of the effects of rIL-4 on the activation half-life of AK cells was possible using lymphocytes from IL-2-treated patients. When these cells were cultured in medium alone. the activation half-life was 18 2 IL-4 was detected in both groups of patients, either in serum during the recovery phase after BMT or as transcripts in circulating lymphocytes during rIL-2 infusion. It is likely that serum levels of IL-4 would also increase in the latter group if the induction signal were sufficiently prolonged, because cells cultured in vitro in the presence of IL-2 released IL-4 protein. The IL-4 released subsequently modifies MHC-unrestricted AK cell function.
Addition of IL-4 to normal donor lymphocytes inhibits the induction phase of AK cell generation. Thus, as previously r e p~r t e d *~~~~'~-~* and confirmed here (Fig 3A) , the response of normal PMBC to the stimulation provided by IL-2 can be largely prevented by simultaneous exposure to IL-4. However, IL-4 has different effects on the function of cytotoxic cells that have already been activated. It is unable to block the response to stimulatory cytokines such as IL-2 once lymphocytes have passed beyond the induction phase of AK cell generation. These differences are illustrated by the interaction of IL-4 and IL-2 with lymphocytes from BMT recipients (Fig 3B) . In these patients, circulating CD16TD3-and CD16TD3' lymphocytes showed evidence of modest activation in vivo? Although the mechanism of this triggering is uncertain, both cell subsets can kill NK-resistant target cells in an MHC-unrestricted manner? This endogenous AK activity can be increased still further Effect of IL-4 on the decay of AK activity. by exposing the cells to rIL-2.29333,34 In this context, IL-4 had no significant effect on the IL-2-induced increase in AK function (Fig 3B) . The limitations of IL-4-mediated inhibition of IL-2-dependent augmentation of AK function can also be seen when the cytokine is added to lymphocytes from patients receiving pharmacologic doses of rIL-2. These patients develop a level of AK function substantially greater than that found physiologically after BMT; activity can be increased still further ex vivo by exposing these already highly activated cells to fresh rIL-2. In this setting, IL-4 was entirely unable to inhibit the enhancement of AK function mediated by fresh IL-2 ( Fig 3C) . Indeed, IL-2-induced AK cells subsequently exposed to high concentrations of IL-4 may actually respond with transiently increased AK funct i~n . '~ These observations do not mean that the IL-4 induced during cell activation has no homeostatic influence on AK cell behavior. Although IL-4 has little effect on the capacity of preactivated lymphocytes to respond to further activating signals, it can nonetheless regulate the duration of activation once the stimulatory signal is removed. Whether AK cells are endogenously produced after BMT or induced by infusion of rIL-2, analysis of the duration of AK function shows that the IL-4 these activated cells produce helps terminate cytotoxic activity. In the presence of neutralizing antibodies to IL-4, an activation half-life of about 18 hours could be increased to about 44 hours (Fig 5) . Similarly, the IL-4 induced during IL-2 infusion may reduce, by IO-fold or more, the amount of TNF and y-IFN that AK cells secrete over a 48-hour period (Tables 1 and 2 ), an effect that will limit recruitment of fresh AK cells.
These results indicate that the IL-4 induced during endogenous or exogenous AK cell generation has two distinct homeostatic roles. The first is to limit the spread of activation by blocking the response of resting cells to activating stimuli (such as IL-2) released into the milieu. The second is to reduce the duration of activation and the quantity of activating cytokines released by those cells activated before IL-4 production has begun.
If the antineoplastic function of AK cells depends on the duration of augmented cytotoxic function as well as on its intensity, then the effects of IL-4 we have described suggest that antibodies to IL-4 or to its receptor could be components of immunotherapy in patients with malignant disease.
